A clinical perspective on gastric neuroendocrine neoplasia

Current Gastroenterology Reports

Volumn 13, Issue 1, 2011, Pages 101-109

  Lawrence, Ben ^a   Kidd, Mark ^a   Svejda, Bernhard ^a   Modlin, Irvin ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Carcinoid; Chemotherapy; Chronic atrophic gastritis; ECLoma; Gastric carcinoid; Gastrin; Multiple endocrine neoplasia 1; Neuroendocrine tumor; Poorly differentiated neuroendocrine carcinoma; Proton pump inhibitor; Well differentiated neuroendocrine carcinoma; Well differentiated neuroendocrine tumor; Zollinger Ellison syndrome

Indexed keywords

CHROMOGRANIN A; CISPLATIN; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; STREPTOZOCIN; SYNAPTOPHYSIN; VESICULAR MONOAMINE TRANSPORTER 2;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL PROLIFERATION; DIFFERENTIAL DIAGNOSIS; ENTEROCHROMAFFIN LIKE CELL; GASTRIC NEUROENDOCRINE TUMOR; GASTROSCOPY; HISTOPATHOLOGY; HUMAN; NEUROENDOCRINE TUMOR; NONHUMAN; PATHOGENESIS; PROGNOSIS; STOMACH ANTRUM RESECTION; STOMACH CARCINOID; SURVIVAL RATE; SURVIVAL TIME; TUMOR VOLUME;

CARCINOID TUMOR; CARCINOMA, NEUROENDOCRINE; CELL TRANSFORMATION, NEOPLASTIC; ENTEROCHROMAFFIN-LIKE CELLS; GASTROSCOPY; HUMANS; INCIDENCE; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NEUROENDOCRINE TUMORS; PROGNOSIS; STOMACH NEOPLASMS;

EID: 79551509350     PISSN: 15228037     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11894-010-0158-4     Document Type: Article

References (58)

1. IM Modlin KD Lye M Kidd 2003 Carcinoid tumors of the stomach Surg Oncol 12 2 153 172 10.1016/S0960-7404(03)00034-3 12946486 (Pubitemid 37289020)
2. G Rindi E Solcia 2007 Endocrine hyperplasia and dysplasia in the pathogenesis of gastrointestinal and pancreatic endocrine tumors Gastroenterol Clin North Am 36 4 851 865 10.1016/j.gtc.2007.08.006 17996794 vi (Pubitemid 350051708)
3. O Nilsson E Van Cutsem G Delle Fave, et al. 2006 Poorly differentiated carcinomas of the foregut (gastric, duodenal and pancreatic) Neuroendocrinology 84 3 212 215 1:CAS:528:DC%2BD2sXhvFSmt7k%3D 10.1159/000098013 17312381 (Pubitemid 46361055)
4. G Rindi O Luinetti M Cornaggia, et al. 1993 Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: a clinicopathologic study Gastroenterology 104 4 994 1006 1:STN:280: DyaK3s3hs1Smuw%3D%3D 7681798
5. MK Washington LH Tang J Berlin, et al. 2010 Protocol for the examination of specimens from patients with neuroendocrine tumors (carcinoid tumors) of the stomach Arch Pathol Lab Med 134 2 187 191 20121605
6. DS Klimstra IR Modlin D Coppola, et al. 2010 The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems Pancreas 39 6 707 712 10.1097/MPA.0b013e3181ec124e 20664470
7. JA Carney VL Go VF Fairbanks, et al. 1983 The syndrome of gastric argyrophil carcinoid tumors and nonantral gastric atrophy Ann Intern Med 99 6 761 766 1:STN:280:DyaL2c%2FnvVSntg%3D%3D 6197001
8. G Rindi C Bordi S Rappel, et al. 1996 Gastric carcinoids and neuroendocrine carcinomas: pathogenesis, pathology, and behavior World J Surg 20 2 168 172 1:STN:280:DyaK28zisFKjtA%3D%3D 10.1007/s002689900026 8661813 (Pubitemid 26069482)
9. T Namikawa M Kobayashi T Okabayashi, et al. 2005 Primary gastric small cell carcinoma: report of a case and review of the literature Med Mol Morphol 38 4 256 261 10.1007/s00795-005-0293-4 16378235 (Pubitemid 351543859)
10. IM Modlin M Kidd KD Lye 2002 Biology and management of gastric carcinoid tumours: a review Eur J Surg 168 12 669 683 1:CAS:528:DC%2BD3sXltVyisLc%3D 10.1080/11024150201680022 15362575 (Pubitemid 36609519)
11. K Borch B Ahren H Ahlman, et al. 2005 Gastric carcinoids: biologic behavior and prognosis after differentiated treatment in relation to type Ann Surg 242 1 64 73 10.1097/01.sla.0000167862.52309.7d 15973103 (Pubitemid 40917969)
12. M Schindl K Kaserer B Niederle 2001 Treatment of gastric neuroendocrine tumors: the necessity of a type-adapted treatment Arch Surg 136 1 49 54 1:STN:280:DC%2BD3M7hslCmtQ%3D%3D 10.1001/archsurg.136.1.49 11146777
13. IM Modlin M Kidd I Latich, et al. 2005 Current status of gastrointestinal carcinoids Gastroenterology 128 6 1717 1751 10.1053/j.gastro.2005.03.038 15887161 (Pubitemid 40692562)
14. Solcia E, Klöppel G, Sobin LH, eds.: Histological Typing of Endocrine Tumors. Berlin: Springer; 2000.
15. DeLellis RA, Lloyd RV, Heitz PU, eds.: World Health Organization Classification of Tumors, Pathology and Genetics of Tumors of Endocrine Organs. Lyon: IARC Press; 2004.
16. P Ruszniewski G Delle Fave G Cadiot, et al. 2006 Well-differentiated gastric tumors/carcinomas Neuroendocrinology 84 3 158 164 1:CAS:528: DC%2BD2sXhvFSmtro%3D 10.1159/000098007 17312375 (Pubitemid 46361049)
17. Edge S, Byrd D, Carducci M, eds.: AJCC Cancer Staging Manual. 7th ed. New York: Springer; 2009.
18. IM Modlin KD Lye M Kidd 2004 A 50-year analysis of 562 gastric carcinoids: small tumor or larger problem? Am J Gastroenterol 99 1 23 32 10.1046/j.1572-0241.2003.04027.x 14687136 (Pubitemid 38679096)
19. Lawrence B, Gustafsson BI, Chan AK, et al.: The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinology and Metabolism Clinics of North America;In Press.
20. AF Li CY Hsu A Li, et al. 2008 A 35-year retrospective study of carcinoid tumors in Taiwan: differences in distribution with a high probability of associated second primary malignancies Cancer 112 2 274 283 10.1002/cncr.23159 18008361
21. O Hauso BI Gustafsson M Kidd, et al. 2008 Neuroendocrine tumor epidemiology: contrasting Norway and North America Cancer 113 10 2655 2664 10.1002/cncr.23883 18853416
22. L Cao T Mizoshita T Tsukamoto, et al. 2008 Development of carcinoid tumors of the glandular stomach and effects of eradication in Helicobacter pylori-infected Mongolian gerbils Asian Pac J Cancer Prev 9 1 25 30 18439067
23. HL Waldum AK Sandvik JR Idle 1998 Gastrin is the most important factor in ECL tumorigenesis Gastroenterology 114 5 1113 1115 1:STN:280: DyaK1c3mtVyitA%3D%3D 10.1016/S0016-5085(98)70346-4 9606099 (Pubitemid 28217581)
24. K Nakata S Aishima H Ichimiya, et al. 2010 Unusual multiple gastric carcinoids with hypergastrinemia: report of a case Surg Today 40 3 267 271 10.1007/s00595-009-4032-7 20180083
25. D Poynter CR Pick RA Harcourt, et al. 1985 Association of long lasting unsurmountable histamine H2 blockade and gastric carcinoid tumours in the rat Gut 26 12 1284 1295 1:CAS:528:DyaL28XivVKksg%3D%3D 10.1136/gut.26.12.1284 2867954
26. AB Thomson MD Sauve N Kassam, et al. 2010 Safety of the long-term use of proton pump inhibitors World J Gastroenterol 16 19 2323 2330 1:CAS:528:DC%2BC3cXmsFCqt7k%3D 10.3748/wjg.v16.i19.2323 20480516
27. DY Graham RM Genta 2008 Long-term proton pump inhibitor use and gastrointestinal cancer Curr Gastroenterol Rep 10 6 543 547 10.1007/s11894-008- 0100-1 19006608
28. EJ Kuipers 2006 Proton pump inhibitors and gastric neoplasia Gut 55 9 1217 1221 1:CAS:528:DC%2BD28XhtVehurjL 10.1136/gut.2005.090514 16905689 (Pubitemid 44277346)
29. RT Jensen 1998 Management of the Zollinger-Ellison syndrome in patients with multiple endocrine neoplasia type 1 J Intern Med 243 6 477 488 1:CAS:528:DyaK1cXks1Wkur4%3D 10.1046/j.1365-2796.1998.00281.x 9681846 (Pubitemid 28312244)
30. MJ Berna B Annibale M Marignani, et al. 2008 A prospective study of gastric carcinoids and enterochromaffin-like cell changes in multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: identification of risk factors J Clin Endocrinol Metab 93 5 1582 1591 1:CAS:528:DC%2BD1cXlvFWhu7Y%3D 10.1210/jc.2007-2279 18270260 (Pubitemid 351656492)
31. C Bordi JY Yu MT Baggi, et al. 1991 Gastric carcinoids and their precursor lesions. A histologic and immunohistochemical study of 23 cases Cancer 67 3 663 672 1:STN:280:DyaK3M%2FptFyiuw%3D%3D 10.1002/1097-0142(19910201)67: 3<663::AID-CNCR2820670323>3.0.CO;2-L 1702355
32. J Strosberg D Coppola D Klimstra, et al. 2010 The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas Pancreas 39 6 799 800 10.1097/MPA.0b013e3181ebb56f 20664477
33. BS Kim ST Oh JH Yook, et al. 2010 Typical carcinoids and neuroendocrine carcinomas of the stomach: differing clinical courses and prognoses Am J Surg 200 3 328 333 10.1016/j.amjsurg.2009.10.028 20385369
34. HL Waldum H Rorvik S Falkmer, et al. 1999 Neuroendocrine (ECL cell) differentiation of spontaneous gastric carcinomas of cotton rats (Sigmodon hispidus) Lab Anim Sci 49 3 241 247 1:STN:280:DyaK1MzjtVagsw%3D%3D 10403437
35. FZ Maempel I Modlin 1978 Diagnosis and management of gastric carcinoid tumour with hepatic metastases Br J Surg 65 7 516 520 1:STN:280: DyaE1c3ht1aiuw%3D%3D 10.1002/bjs.1800650721 667550
36. MH Kulke LB Anthony DL Bushnell, et al. 2010 NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas Pancreas 39 6 735 752 10.1097/MPA.0b013e3181ebb168 20664472
37. C Karaca BG Turner S Cizginer, et al. 2010 Accuracy of EUS in the evaluation of small gastric subepithelial lesions Gastrointest Endosc 71 4 722 727 10.1016/j.gie.2009.10.019 20171632
38. RA Gladdy VE Strong D Coit, et al. 2009 Defining surgical indications for type I gastric carcinoid tumor Ann Surg Oncol 16 11 3154 3160 10.1245/s10434-009-0687-y 19727959
39. FE Eckhauser RV Lloyd NW Thompson, et al. 1988 Antrectomy for multicentric, argyrophil gastric carcinoids: a preliminary report Surgery 104 6 1046 1053 1:STN:280:DyaL1M%2FlvVyjsA%3D%3D 3194832
40. M Hoshino N Omura F Yano, et al. 2010 Usefulness of laparoscope-assisted antrectomy for gastric carcinoids with hypergastrinemia Hepatogastroenterology 57 98 379 382 20583448
41. J Ozao-Choy K Buch JA Strauchen, et al. 2010 Laparoscopic antrectomy for the treatment of type I gastric carcinoid tumors J Surg Res 162 1 22 25 10.1016/j.jss.2010.01.005 20421108
42. M Kidd LH Tang IM Modlin, et al. 2000 Gastrin-mediated alterations in gastric epithelial apoptosis and proliferation in a mastomys rodent model of gastric neoplasia Digestion 62 2-3 143 151 1:CAS:528:DC%2BD3cXns1GisL8%3D 10.1159/000007806 11025361
43. M Kidd IM Modlin JW Black, et al. 2007 A comparison of the effects of gastrin, somatostatin and dopamine receptor ligands on rat gastric enterochromaffin-like cell secretion and proliferation Regul Pept 143 1-3 109 117 1:CAS:528:DC%2BD2sXovFGnsrg%3D 10.1016/j.regpep.2007.04.002 17531331 (Pubitemid 47212532)
44. MS Khuroo NS Khuroo 2010 Treatment of type I gastric neuroendocrine tumors with somatostatin analogs J Gastroenterol Hepatol 25 3 548 554 1:CAS:528:DC%2BC3cXlt1Siu78%3D 10.1111/j.1440-1746.2009.06131.x 20074162
45. V Fykse AK Sandvik HL Waldum 2005 One-year follow-up study of patients with enterochromaffin-like cell carcinoids after treatment with octreotide long-acting release Scand J Gastroenterol 40 11 1269 1274 10.1080/ 00365520510023684 16334435 (Pubitemid 41658724)
46. S Grozinsky-Glasberg G Kaltsas C Gur, et al. 2008 Long-acting somatostatin analogues are an effective treatment for type 1 gastric carcinoid tumours Eur J Endocrinol 159 4 475 482 1:CAS:528:DC%2BD1cXhtlSrtbzO 10.1530/EJE-08-0420 18662970
47. D Campana F Nori R Pezzilli, et al. 2008 Gastric endocrine tumors type I: treatment with long-acting somatostatin analogs Endocr Relat Cancer 15 1 337 342 1:CAS:528:DC%2BD1cXkslKnu7c%3D 10.1677/ERC-07-0251 18310299 (Pubitemid 351449751)
48. P Ruszniewski A Ramdani G Cadiot, et al. 1993 Long-term treatment with octreotide in patients with the Zollinger-Ellison syndrome Eur J Clin Invest 23 5 296 301 1:STN:280:DyaK3szlvV2lug%3D%3D 10.1111/j.1365-2362.1993.tb00777.x 8354336
49. B Annibale 1994 Delle Fave G, Azzoni C, et al.: Three months of octreotide treatment decreases gastric acid secretion and argyrophil cell density in patients with Zollinger-Ellison syndrome and antral G-cell hyperfunction Aliment Pharmacol Ther 8 1 95 104 1:STN:280:DyaK2c3kt1yqtg%3D%3D 10.1111/j.1365-2036.1994.tb00165.x 7910489
50. S Manfredi M Pagenault AS de Lajarte-Thirouard, et al. 2007 Type 1 and 2 gastric carcinoid tumors: long-term follow-up of the efficacy of treatment with a slow-release somatostatin analogue Eur J Gastroenterol Hepatol 19 11 1021 1025 10.1097/MEG.0b013e328220eae0 18049175 (Pubitemid 350287412)
51. Lawrence B, Gustaffson B, Kidd M, et al.: New Pharmacologic Therapies for Gastroenteropancreatic Neuroendocrine Tumors. North American Clinics of Gastroenterology 2010;in press.
52. CG Moertel LK Kvols MJ O'Connell, et al. 1991 Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms Cancer 68 2 227 232 1:STN:280:DyaK3MzgtVCjuw%3D%3D 10.1002/1097-0142(19910715)68:2<227::AID- CNCR2820680202>3.0.CO;2-I 1712661
53. E Mitry E Baudin M Ducreux, et al. 1999 Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin Br J Cancer 81 8 1351 1355 1:CAS:528:DC%2BD3cXls1KksA%3D%3D 10.1038/sj.bjc.6690325 10604732
54. MH Kulke B Wu DP Ryan, et al. 2006 A phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumors Dig Dis Sci 51 6 1033 1038 1:CAS:528:DC%2BD28Xnt1yju7c%3D 10.1007/s10620-006-8001-3 16865563 (Pubitemid 44127047)
55. IM Modlin KD Lye M Kidd 2003 A 5-decade analysis of 13, 715 carcinoid tumors Cancer 97 4 934 959 10.1002/cncr.11105 12569593 (Pubitemid 36173145)
56. G Rindi C Azzoni S La Rosa, et al. 1999 ECL cell tumor and poorly differentiated endocrine carcinoma of the stomach: prognostic evaluation by pathological analysis Gastroenterology 116 3 532 542 1:STN:280: DyaK1M7lsFaksw%3D%3D 10.1016/S0016-5085(99)70174-5 10029611
57. S Rappel A Altendorf-Hofmann M Stolte 1995 Prognosis of gastric carcinoid tumours Digestion 56 6 455 462 1:STN:280:DyaK287islGisg%3D%3D 10.1159/000201276 8536814
58. CS Landry G Brock CR Scoggins, et al. 2009 A proposed staging system for gastric carcinoid tumors based on an analysis of 1, 543 patients Ann Surg Oncol 16 1 51 60 10.1245/s10434-008-0192-8 18953609